Skip to main content
. 2020 Nov 30;4(4):e383–e392. doi: 10.1055/s-0040-1720961

Fig. 2.

Fig. 2

( A ) Outcomes of oral anticoagulant (OAC) treatment versus no treatment/placebo in randomized controlled trials; stroke, myocardial infarction, all-cause mortality and major bleeding. ( B ) Outcomes of oral anticoagulant treatment versus antiplatelet therapy in randomized controlled trials; stroke, myocardial infarction, all-cause mortality and major bleeding. ( C ) All-cause mortality of oral anticoagulant treatment versus no treatment in cohort studies. ( D ) Sensitivity analysis for outcomes of oral anticoagulant treatment versus no treatment/placebo in randomized controlled trials without the COMMANDER HF 2018 study; stroke, myocardial infarction, all-cause mortality and major bleeding. CI, confidence interval; COMMANDER HF, a study to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, myocardial infarction, or stroke in participants with HF and coronary artery disease following an episode of decompensated heart failure; OR, odds ratio.